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Abstract
Background: Myoclonus can be a clinical manifestation of numerous neurodegenerative disorders and an adverse drug reaction to medications used in their
treatment.
Case Report: Herein, we report memantine-induced myoclonus in a patient with Alzheimer disease. The myoclonus seen in our patient was generalized
(proximal limbs and trunk), present at rest and with action, and stimulus sensitive. A structured evaluation with the Unified Myoclonus Rating Scale showed that the
myoclonus had no significant effect on functional capacity. After discontinuation of memantine, myoclonus slowly resolved over the course of several weeks.
Discussion: Memantine may cause myoclonus in susceptible individuals.
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Introduction
Myoclonus is a clinical sign defined as sudden, brief, shock like,
involuntary movements caused by muscular contractions or inhibi-
tions. Myoclonus can be seen in dementing neurodegenerative
disorders of varied etiologies including Creutzfeldt–Jakob disease,
Alzheimer disease, dementia with Lewy bodies, and frontotemporal
dementia.1 Myoclonus is also one known, albeit rare, side effect of
drugs used to treat dementia and other neurological disorders. The
possibility of drug-induced myoclonus in subjects with dementia and
related neurodegenerative disorders may be ignored. Here we present
a case of myoclonus in a patient with Alzheimer dementia whose
myoclonus recovered completely after withdrawal of memantine.
Written informed consent was obtained for publication of the case
report and accompanying videos.
Case report
An 89-year-old male presented to us with a 7-year history of
progressive cognitive decline and 5-year history of myoclonus. The
myoclonus was generalized in distribution, mainly in the trunk and
limbs, and present both at rest and with activity. There were no
associated falls or notable functional limitations due to the myoclonus.
At the time of initial evaluation, he was receiving memantine 10 mg
twice daily for cognitive impairment, previously diagnosed as
Alzheimer disease. Myoclonus was being treated with levetiracetam
1000 mg twice daily, clonazepam 0.25 mg daily, and divalproex sodium
extended release 500 mg twice daily. Over the course of approximately
2 years, there was minimal subjective or documented clinical benefit
from levetiracetam, in isolation, or the combination of levetiracetam,
clonazepam, and divalproex sodium. He was also receiving medications
for essential hypertension (amlodipine and hydralazine), hypercholes-
terolemia (simvastatin) and hypothyroidism (levoxyl). Upon detailed
review of historical events, the patient’s wife confirmed that the
appearance of myoclonus was temporally associated with initiation of
therapy with memantine. She had failed to recognize this association
during clinic visits with the referring general neurologist.
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Prior to the addition of memantine, the patient’s Alzheimer disease
was initially treated with transdermal rivastigmine up to 13.3 mg daily.
Rivastigmine was discontinued due to apparent lack of efficacy with
steady decline in cognition over several years. Magnetic resonance
imaging of the brain showed moderate generalized atrophy and mild
microangiopathy. Electroencephalography (EEG) obtained with the
patient awake and asleep was mildly abnormal due to frequent left
temporal slowing in the delta range. Although myoclonus was present
during the EEG, there were no apparent neurophysiological
correlates. No epileptiform activity was noted on EEG. The EEG
background was slow and disorganized with mixed alpha and theta
frequencies and absence of a well-recognized posterior alpha rhythm.
Bilateral upper limb somatosensory evoked potential studies (SSEPs)
were normal.
On physical examination, the pulse was 68/minute and regular,
and blood pressure was 130/60 mmHg. The Mini-Mental State
Examination score was 20 out of 30 with marked deficits in recall
(0/3) and orientation (3/10). Cranial nerve examination was normal:
there was no weakness or sensory loss, deep tendon reflexes were
normal, and planters were down. A snout reflex was present. The
Unified Myoclonus Rating Scale (UMRS)2 was videotaped.
Myoclonus was most prominent in the proximal legs followed by
the trunk and arms without facial involvement (Video Segment 1A).
The following UMRS scores were obtained: patient questionnaire
(6/44), patient global disability assessment (1/4), myoclonus at rest
(10/128), stimulus sensitivity (10/17), myoclonus with action (5/160),
functional tests (0/28), and physician global disability score (1/4).
Myoclonus was elicited by unexpected handclaps, nose taps, jaw jerks,
pin pricks to the bottom of the feet, toe flicks, and taps to the biceps
tendons. There was no evidence for negative myoclonus on
examination. The patient’s myoclonus exerted mildly deleterious
effects on eating, drinking, dressing, rising from a seated position,
standing, and walking.
Laboratory studies showed normal blood glucose, vitamin B12,
folate, serum electrolytes, and liver function tests. Mild anemia
(hematocrit 37.6%, reference range 39–55%), and mild elevations in
serum creatinine (1.47 mg/dL, reference range 0.6–1.3 mg/dL), blood
urea nitrogen (34 mg/dL, reference range 7–25 mg/dL) and thyroid
stimulating hormone (5.88 uIU/mL, 0.35–5.5 mIU/mL) were noted.
Memantine was tapered off over the course of 4 weeks with
moderate reduction in the frequency and severity of myoclonus.
According to the patient’s spouse, myoclonus did not completely
resolve until several weeks after the final dose of memantine. Follow-up
examination with repeat UMRS 3 months after the initial UMRS
showed complete resolution of stimulus-sensitive, rest and action
myoclonus (Video Segment 1B). Upon resolution of myoclonus,
levetiracetam and divalproex sodium were discontinued without
consequence. The patient continued to take an occasional dose of
0.25 mg of clonazepam for sleep. Resolution of myoclonus was
Video Segment 1A. Baseline. This video shows generalized myoclonus present at rest, with action, and in response to stimuli. Myoclonus is maximal in the
proximal legs followed by the trunk and arms. Segment 1B. Video at 3-month Follow-up. No myoclonus seen at rest or with stimuli.
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associated with mild improvements in the subject’s ability to eat, drink,
dress, stand, and walk.
A total score of 4 was obtained upon applying the Naranjo Adverse
Drug Reaction Probability Scale,3 suggesting that the myoclonus in
our patient was a possible adverse reaction to memantine. The
Naranjo score is derived from a 10-item questionnaire and scores
range from 0 to >9. The probability of an adverse drug reaction is
assigned as definite (>9), probable (5–8), possible (1–4), or doubtful (0).
Discussion
Memantine is a low-to-moderate affinity, uncompetitive (open-
channel), voltage-dependent, NMDA (N-methyl-D-aspartic acid)-receptor
antagonist with fast on/off kinetics that inhibit excessive calcium influx
induced by chronic overstimulation of the NMDA receptor. Memantine is
approved in the United States for the treatment of patients with moderate-
to-severe dementia of the Alzheimer type.4 Memantine is largely excreted
unchanged by the kidney and caution should be used in patients with
significant renal impairment. Overall, drugs used for dementia cause
approximately 4% of drug-induced myoclonus, and cholinesterase
inhibitors are the most common culprits.5 Drug-induced myoclonus can
be cortical or subcortical origin. In patients with drug-induced myoclonus,
a cortical origin is supported by the presence of EEG spikes and large
amplitude SSEPs.6,7
Our review of the literature identified only three reports of
myoclonus associated with memantine.8–10 All three of these
previously described patients had Alzheimer disease and two of the
three had renal impairment, which may have contributed to the
toxicity of memantine.8–10 Although one report included a video that
documents myoclonus,10 myoclonus was not robustly characterized in
these reports and the UMRS was not employed as part of the
neurological evaluations. However, as seen in our patient, memantine-
induced myoclonus was described as generalized in these earlier
publications. The normal SSEPs, normal EEG, stimulus sensitivity,
and predominant involvement of the proximal limbs and trunk are
most compatible with a subcortical origin. In addition, a subcortical
origin is supported by the lack of improvement with medications that
act principally to suppress cortical myoclonus.
Myoclonus is a common clinical manifestation of Alzheimer
disease.11 In one study, 8% of patients with Alzheimer disease had a
myoclonic variant characterized by presenile onset with severe
cognitive deterioration, mutism, and early-onset myoclonus.12
Myoclonus is more commonly seen in early-onset and rapidly
progressive Alzheimer disease, where its prevalence may be as high as
75%.13 Myoclonus in Alzheimer disease can be classified into cortical
and subcortical types. The cortical variety is more common.14,15
Subcortical myoclonus may have its origin in the brainstem, and
autopsy studies have shown reduced numbers of neurons in the locus
coeruleus and raphe nucleus in these patients.16 The myoclonus in
Alzheimer disease may be multifocal or generalized and it can occur at
rest, action, or in response to stimuli.17
The cellular and network origins of myoclonus in patients taking
memantine are not known. Amantadine, which has a similar
mechanism of action to memantine, has been shown to produce
myoclonus. Both drugs act by blocking NMDA glutamate receptors.
There have been reports of amantadine-induced myoclonus in patients
with Parkinson disease and progressive supranuclear palsy.18,19
Myoclonus slowly disappeared over a period of 3–4 weeks after
withdrawal of memantine, suggesting that some neuronal changes
induced by memantine persist long after the drug has been cleared
from the system. It is possible that memantine induces long-term
changes in neuronal firing properties by altering the expression of
secondary- or delayed-response genes. In this regard, memantine has
been shown to alter the expression of genes in rat brain encoding
kinases, phosphatases, G-protein coupled receptors, vesicle and
synaptic proteins, and neuropeptides.20
Based on clinical examination alone it can be difficult to
differentiate drug-induced myoclonus from the myoclonus of degen-
erative dementias. An acute onset and clear temporal association with
initiation of medication would point towards drug-induced myoclonus.
Additional evidence for drug-induced myoclonus includes previous
valid reports of causality in the referred literature, resolution with
discontinuation of the medication, and correlations between myoclo-
nus severity and drug dosage.
To conclude, myoclonus may be seen as an adverse reaction to
memantine in patients with Alzheimer disease and, perhaps, other
neurodegenerative disorders. Given that myoclonus is relatively
common in Alzheimer disease, clinicians must maintain a high index
of suspicion of an adverse drug reaction when myoclonus appears in
this patient population. Moreover, myoclonus may take weeks to
resolve after discontinuation of memantine.
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